Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Debt (2016 - 2024)

Historic Non-Current Debt for Capricor Therapeutics (CAPR) over the last 12 years, with Q3 2024 value amounting to $3.4 million.

  • Capricor Therapeutics' Non-Current Debt changed 0.0% to $3.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.4 million for FY2023, which is 0.0% changed from last year.
  • Capricor Therapeutics' Non-Current Debt amounted to $3.4 million in Q3 2024, which was down 0.0% from $3.4 million recorded in Q2 2024.
  • Capricor Therapeutics' 5-year Non-Current Debt high stood at $3.4 million for Q1 2020, and its period low was $3.4 million during Q1 2020.
  • Over the past 5 years, Capricor Therapeutics' median Non-Current Debt value was $3.4 million (recorded in 2020), while the average stood at $3.4 million.
  • The largest annual percentage gain for Capricor Therapeutics' Non-Current Debt in the last 5 years was 0.0% (2020), contrasted with its biggest fall of 0.0% (2020).
  • Quarter analysis of 5 years shows Capricor Therapeutics' Non-Current Debt stood at $3.4 million in 2020, then changed by 0.0% to $3.4 million in 2021, then changed by 0.0% to $3.4 million in 2022, then changed by 0.0% to $3.4 million in 2023, then changed by 0.0% to $3.4 million in 2024.
  • Its Non-Current Debt stands at $3.4 million for Q3 2024, versus $3.4 million for Q2 2024 and $3.4 million for Q1 2024.